Literature DB >> 9487252

Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI).

A R Exley1, P A Bacon, R A Luqmani, G D Kitas, D M Carruthers, R Moots.   

Abstract

Assessment of disease severity in systemic vasculitis encompasses mortality, which is now uncommon, and morbidity, which is increasing in significance. Morbidity includes permanent scars or damage, an evolving concept offering a novel perspective which may be particularly valuable in chronic disease. We have developed a method for assessing damage in systemic vasculitis, but the relationship between damage and disease severity was unknown. Therefore, we examined whether the number of items of damage or the pattern of damage varied with the severity of systemic vasculitis. We established the characteristics of severe disease by examining fatal vasculitis as an example of the most severe disease possible. We then showed that more damage occurred in fatal vasculitis, more systems were damaged, and critical damage akin to organ failure was more common in fatal than non-fatal vasculitis. These observations were reproduced in specific diagnostic groups, namely classical Wegener's granulomatosis and systemic rheumatoid vasculitis. Thus, severe disease was characterized by many items of damage, multisystem damage and critical damage. This pattern of damage was also seen in a subgroup of patients with non-fatal vasculitis, who also have severe disease.

Entities:  

Mesh:

Year:  1998        PMID: 9487252     DOI: 10.1093/rheumatology/37.1.57

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  21 in total

Review 1.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Clinical management and treatment of vasculitis.

Authors:  D Jayne
Journal:  Springer Semin Immunopathol       Date:  2001

Review 3.  Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?

Authors:  O Flossmann; R B Jones; D R W Jayne; R A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-07       Impact factor: 19.103

Review 4.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors:  Bernhard Hellmich; Oliver Flossmann; Wolfgang L Gross; Paul Bacon; Jan Willem Cohen-Tervaert; Loic Guillevin; David Jayne; Alfred Mahr; Peter A Merkel; Heiner Raspe; David G I Scott; James Witter; Hasan Yazici; Raashid A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

Review 5.  Development of comprehensive disease assessment in systemic vasculitis.

Authors:  Oliver Flossmann; Paul Bacon; Kirsten de Groot; David Jayne; Niels Rasmussen; Philip Seo; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2006-05-25       Impact factor: 19.103

6.  Wegener's granulomatosis: experience from a Brazilian tertiary center.

Authors:  Fernando Henrique Carlos de Souza; Ari Stiel Radu Halpern; Carmen Silvia Valente Barbas; Samuel Katsuyuki Shinjo
Journal:  Clin Rheumatol       Date:  2010-03-01       Impact factor: 2.980

7.  Reduced survival in microscopic polyangiitis patients with pulmonary fibrosis in a respiratory referral centre.

Authors:  Luis Felipe Flores-Suárez; Natllely Ruiz; Lina María Saldarriaga Rivera; Lya Pensado
Journal:  Clin Rheumatol       Date:  2015-05-17       Impact factor: 2.980

Review 8.  [Renal manifestations of rheumatic diseases].

Authors:  A Schwarting; E Märker-Hermann
Journal:  Z Rheumatol       Date:  2005-02       Impact factor: 1.372

9.  Evaluation of damage in giant cell arteritis.

Authors:  Tanaz A Kermani; Antoine G Sreih; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Paul A Monach; Larry Moreland; Christian Pagnoux; Philip Seo; Kenneth J Warrington; Steven R Ytterberg; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2018-02-01       Impact factor: 7.580

10.  Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis.

Authors:  Sophie Ohlsson; Omran Bakoush; Jan Tencer; Ole Torffvit; Mårten Segelmark
Journal:  Mediators Inflamm       Date:  2009-07-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.